# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst David Amsellem reiterates Indivior (NASDAQ:INDV) with a Overweight and maintains $22 price target.
Primary and Secondary End Points of the Study were Not Met Indivior Does Not Currently Expect to Exercise AEF0117 Option
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatmen...
BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal sprayThrough BARDA's contract with Indivior, communities ...